Financial Performance - gategroup generated revenues of EUR 5.61 billion for the financial year ending December 31, 2025, an increase from EUR 5.47 billion in 2024 [1] - EBITDA reached EUR 467 million, up from EUR 410 million in 2024, resulting in an EBITDA margin of 8.3 percent compared to 7.5 percent in the previous year [1] - Net debt/EBITDA ratio improved to 3.25x from 3.74x in 2024, indicating a stronger balance sheet [1] - Gross capital expenditures for the period amounted to EUR 88 million, an increase from EUR 72 million in 2024 [1] Currency Transition - gategroup is transitioning its reporting currency from Swiss Francs (CHF) to Euros (EUR) to better align with its revenue generation and global operations [2] - The 2025 annual report will be published in EUR in early April 2026 after the completion of the full audit [2] Strategic Initiatives - gategroup successfully completed a bond repurchase tender for its CHF 350 million bond maturing in February 2027, with CHF 92 million in bonds tendered and accepted [3] - The company is evaluating a range of strategic options to support future growth, including a potential public listing, although no decision has been made yet [4] Company Overview - gategroup is a leading global provider of airline catering, retail-on-board, and hospitality products and services, headquartered in Zurich, Switzerland [5] - The company serves millions of passengers through a network of nearly 300 locations in over 68 countries, partnering with leading airlines to enhance travel experiences [5]

Core Insights - CROSSJECT has made significant progress in the development and regulatory preparation of ZEPIZURE®, an injectable for managing epileptic seizures, with a focus on its proprietary ZENEO® needle-free auto-injector technology [1][5][6] Financial Performance - For the financial year ending December 31, 2025, CROSSJECT reported operating revenue of €14.9 million, a 12.2% increase from €13.3 million in 2024, primarily driven by BARDA invoicing which rose to €12.1 million from €8.2 million [3][14] - Operating expenses increased slightly to €26.5 million from €26.2 million in 2024, resulting in an operating loss of €11.6 million, an improvement from a loss of €13.0 million in 2024 [15][16] - The net loss for 2025 was €10.4 million, improved from €12.8 million in 2024, reflecting better revenue growth and disciplined expenditure management [16] Funding and Financial Structure - CROSSJECT received increased funding from BARDA, totaling $43.3 million, which supports regulatory and manufacturing activities [2][8] - The company reduced its bank debt by €2.7 million, with borrowings from credit institutions decreasing to €10.2 million from €12.9 million at the end of 2024 [4][18] - As of December 31, 2025, CROSSJECT had available cash of €5.1 million, supplemented by a €2.8 million research tax credit receivable, totaling €7.9 million [3][20] Regulatory and Operational Developments - In 2025, CROSSJECT achieved satisfactory stability results for ZEPIZURE® and produced additional validation batches, preparing for regulatory submissions [6][9] - The company is actively pursuing an Emergency Use Authorization (EUA) application in coordination with BARDA, aiming for commercial deliveries in 2026 and U.S. commercialization in 2027 [5][23] Strategic Direction - CROSSJECT is focusing on the development of its ZENEO® platform, including ZEPIZURE® Junior for pediatric use, and estimates the commercial potential of its emergency medicines portfolio could reach annual peak sales of around €1 billion [10][9] - The company has strengthened its governance and market visibility, with new coverage initiated by financial institutions and preparations for direct commercialization in the U.S. [12][13]

Core Insights - The Board of Directors of OVH Groupe S.A. has decided to reallocate approximately 850,000 treasury shares for future external growth transactions instead of employee stock ownership plans [1] - As of the Board meeting date, around 1,315,228 shares are allocated for free share plans and employee participation in company expansion and savings plans [2] Company Overview - OVHcloud is a leading European cloud provider with over 500,000 servers across 46 data centers on 4 continents, serving 1.6 million customers in more than 140 countries [3] - The company emphasizes a sustainable cloud model with a strong performance-price ratio, maintaining control over its entire value chain from server design to data center management [3] - OVHcloud offers advanced solutions that ensure performance, predictable pricing, and data sovereignty to support customer growth [3]

Group 1: Acquisition Overview - OVHcloud has signed a binding agreement to acquire Dragon LLM, an AI model fine-tuning platform aimed at regulated industries, to enhance its expertise in generative AI [1][2] - This acquisition marks the first for OVHcloud and initiates the launch of its AI lab, which will focus on training and fine-tuning sovereign LLM models [2] Group 2: About Dragon LLM - Dragon LLM, originally founded as Lingua Custodia, specializes in developing sovereign generative AI models tailored for the financial sector and has won the Large AI Grand Challenge by the European Commission [2] - The company is based in Paris and aims to create responsible and efficient European AI solutions that support technological sovereignty [2] Group 3: About OVHcloud - OVHcloud is a leading European cloud provider with over 500,000 servers across 46 datacenters on 4 continents, serving 1.6 million customers in more than 140 countries [3] - The company has over 20 years of experience in providing a trusted and sustainable cloud model, ensuring total control over its value chain from server design to datacenter management [3] - OVHcloud offers cutting-edge solutions that combine performance, predictable pricing, and complete data sovereignty, promoting environmentally conscious practices [3]

Core Insights - The phase 2 trial results for UBT251, a triple agonist for type 2 diabetes, show significant efficacy in reducing HbA1c and body weight compared to placebo and semaglutide [2][7][8] Company Overview - United Laboratories International Holdings Limited (TUL) is engaged in the research, development, production, and sales of pharmaceuticals, ranking among the leading integrated pharmaceutical companies in China [11] - TUL's subsidiary, United Biotechnology, is responsible for the development of UBT251 in Chinese mainland, Hong Kong, Macau, and Taiwan, while Novo Nordisk handles the rest of the world [2][10] Clinical Trial Results - The trial enrolled 211 Chinese patients with type 2 diabetes, showing a mean HbA1c reduction of 2.16% for UBT251 compared to 1.77% for semaglutide and 0.66% for placebo after 24 weeks [2][6][7] - UBT251 also demonstrated a mean body weight reduction of up to 9.8%, compared to 4.8% for semaglutide and 1.4% for placebo [2][7] - Key secondary endpoints, including waist circumference, blood pressure, and lipids, showed improvements with UBT251 relative to placebo [3] Future Developments - TUL plans to advance to phase 3 trials in China based on the positive phase 2 results [4][5] - Novo Nordisk will initiate a global phase 2 trial for UBT251 in type 2 diabetes later in 2026 and is already conducting a global phase 2 trial in weight management [4][5]

Core Insights - Zelluna ASA is focused on pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies aimed at treating solid cancers [1] - The Board of Directors of Zelluna ASA has approved the Annual Report for the year 2025 [1] - The Annual Report is available in PDF format and in European Single Electronic Format (ESEF), and can also be accessed on the company's website [1] Company Information - Zelluna ASA's Chairman of the Board is Anders Tuv, and the CEO is Namir Hassan [2] - The CFO of Zelluna ASA is Geir Christian Melen [2] - Contact information for the company's leadership is provided for further inquiries [2]

Core Insights - Vallourec has secured five contracts for OCTG products in Indonesia, totaling approximately 36,000 tons to support Oil & Gas operations for around 140 wells [2][3]. Group 1: Contracts and Volume - The company signed two contracts in February 2026 for 14,000 tons of OCTG products, part of the total five contracts [2]. - The total volume of the contracts is approximately 36,000 tons of premium pipes and connections [2]. Group 2: Technical Challenges and Solutions - The projects are primarily located in deep offshore environments, highlighting the technical challenges of Indonesia's energy sector [3]. - Vallourec will supply advanced connections, including VAM 21, which is recognized for its safe and reliable performance under high pressures and extreme conditions [3]. Group 3: Local Production and Value - The pipes will be heat treated and threaded at Vallourec's subsidiary in Indonesia, maximizing local production and adding value to the country [4]. - The company's long-standing relationships with key oil & gas players in Indonesia are emphasized, showcasing market recognition of product quality [5].

Core Viewpoint - Tecan Group is proposing significant changes to its Board of Directors during the upcoming Annual General Meeting, including the election of three new members and a new Chairman, while maintaining a stable dividend of CHF 3.00 per share to reflect confidence in the company's future [1][7]. Board Composition - The Board of Directors will propose the election of three new members: Gitte Pugholm Aabo, Guillaume Daniellot, and Nina Beikert, who brings extensive experience in clinical diagnostics [3][9]. - Lukas Braunschweiler, the current Chairman, and Oliver Fetzer will not stand for re-election, while Matthias Gillner is nominated to succeed Braunschweiler as Chairman [2][4][9]. - Four current members, Myra Eskes, Matthias Gillner, Christa Kreuzburg, and Daniel A. Marshak, are proposed for re-election for a one-year term [4][9]. Compensation Committee - The Board proposes the re-election of all current members of the Compensation Committee: Myra Eskes, Christa Kreuzburg, and Daniel A. Marshak, with Eskes expected to continue as Chair [5][9]. Sustainability Reporting - Tecan will submit a report on non-financial matters for approval, which has undergone a limited assurance audit by Ernst & Young AG, demonstrating the company's commitment to sustainability [6][9]. Dividend Proposal - The Board of Directors proposes an unchanged dividend of CHF 3.00 per share, with half of the dividend being paid from the available capital contribution reserve, thus not subject to withholding tax [7][9]. Company Overview - Tecan is a leader in laboratory automation, founded in Switzerland in 1980, with 3,000 employees and operations in over 70 countries. In 2025, the company generated sales of CHF 883 million (USD 1,063 million; EUR 939 million) [10].

Core Insights - Mowi has published its 2025 Integrated Annual Report, which includes sustainability reporting and complete annual accounts with notes [1] - The integrated report is available in European Single Electronic Format (ESEF) and can be accessed on Mowi's investor relations website [1] Company Reporting - The 2025 Integrated Annual Report includes detailed financial information and sustainability metrics [1] - The report is subject to the disclosure requirements of the Norwegian Securities Trading Act [1] Accessibility - The report can be found at www.mowi.com/investors/reports/ [1]

Company Announcement - Yimutian Inc. announced the resignation of independent director Junchen Sun from the Board of Directors, effective March 17, 2026, due to personal reasons [1] - The Company and the Board expressed gratitude for Mr. Sun's service and contributions during his tenure [1] Governance Process - The Nominating and Corporate Governance Committee will oversee the process of identifying a potential replacement for the resigned director [2] - The Company will ensure appropriate disclosures are made in accordance with applicable laws and regulations [2] Company Overview - Yimutian Inc. is a leading agricultural B2B platform in mainland China, focused on digitalizing the agricultural product supply chain infrastructure [3] - The Company aims to streamline the agricultural product transaction process, making it efficient, transparent, secure, and convenient [3]